Search company, investor...
Cerebain Biotech company logo

Cerebain Biotech


Acquired | IPO

About Cerebain Biotech

Cerebain Biotech (OTC: CBBT) is an early-stage drug development company focused on the treatment of Alzheimer's disease. In March 2012, Cerbain Biotech was acquired by Discount Dental Materials through a reverse merger. The valuation of Cerbain Biotech was undisclosed. Other terms of the deal were not released. As a result of the transaction, Cerebain is a wholly-owned subsidiary of the Company.

Headquarters Location

92 Corporate Park Suite C141

Irvine, California, 92606,

United States


Missing: Cerebain Biotech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cerebain Biotech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Cerebain Biotech News

Cerebain Biotech Has Made a Capital Investment in Diabetes Reversal Group, LLC

Sep 29, 2022

September 29, 2022 08:30 AM Eastern Daylight Time COSTA MESA, Calif.--( BUSINESS WIRE )--Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announced that it has made a capital investment in Diabetes Reversal Group, LLC. “Cerebain is happy to announce it has made a capital investment in Diabetes Reversal Group, LLC (DRG). We are confident in the growth potential of DRG due to the size of the diabetes market and the demand for ways to reverse this epidemic disease,” says Eric Clemons, CEO of Cerebain. DRG has the only patented system in the world that reverses Type 2 Diabetes, and they guarantee results. They have a 13-year track record and have helped thousands of diabetics reverse their disease once and for all and get off their medications. “We are excited to expand nationally and internationally with our incredible program, so we can help diabetics reverse this disease that causes so many devastating complications,” says Kristine Burke, MD, who is triple board certified and the Chief Medical Officer of DRG. About Cerebain Biotech Corp. Cerebain Biotech Corp. is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at or connect with us on Twitter and Facebook to learn more. About Diabetes Reversal Group, LLC Diabetes Reversal Group, LLC was founded to provide a natural diabetes treatment, non-drug approach to helping people with metabolic and nutritional imbalances. These imbalances can lead to many health problems traditionally treated with invasive prescription drug therapy, such as Type 2 Diabetes, Neuropathy and Heart Disease. The Patented program developed by DRG helps Type 2 Diabetes, Neuropathy and Heart Disease by restoring proper metabolic function and nutritional balance. We have seen remarkable results with the improvement or elimination of these conditions, working in conjunction with your primary physician. Visit us at . Forward Looking Statements This news release contains certain "forward- looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. Contacts

Cerebain Biotech Frequently Asked Questions (FAQ)

  • Where is Cerebain Biotech's headquarters?

    Cerebain Biotech's headquarters is located at 92 Corporate Park, Irvine.

  • What is Cerebain Biotech's latest funding round?

    Cerebain Biotech's latest funding round is Acquired.

  • Who are the investors of Cerebain Biotech?

    Investors of Cerebain Biotech include Discount Dental Materials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.